無料セミナー : 2020年3月13日『世界における腹腔鏡手術用ロボット市場の展望』 DRG社共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の核医学治療薬市場の分析と予測:アルファ線核種、ベータ線核種、小線源療法

Nuclear Medicine Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 353789
出版日 ページ情報 英文 120 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.91円で換算しております。
Back to Top
世界の核医学治療薬市場の分析と予測:アルファ線核種、ベータ線核種、小線源療法 Nuclear Medicine Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年02月01日 ページ情報: 英文 120 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

世界の核医学治療市場は、2014年の10億9000万米ドルから2019年にかけて20億9000万ドルへ、13.91%のCAGRで成長すると予測されています。

当レポートでは、世界の核医学治療市場について調査し、市場の概要、治療法・治療領域・地域別の市場動向、市場規模の推移と予測、市場成長・阻害要因ならびに市場機会・脅威の分析、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場規模の推定

第2章 主要な所見

第3章 エグゼクティブサマリー

第4章 市場概要

  • 放射性医薬品の定義
  • 市場シェア分析
  • 市場の動向
    • 市場の成長要因
    • 市場の阻害要因
    • 市場機会
    • 脅威

第5章 市場セグメンテーション

  • 治療法別
    • ベータ線核種による治療
    • アルファ線核種による治療
    • 近接照射療法
  • 治療領域別
    • 甲状腺
    • 骨転移
    • リンパ腫
    • 内分泌腫瘍
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第6章 競合情勢

  • 買収・合併
  • 新製品の発売
  • 合意・協力
  • 事業拡張

第7章 企業プロファイル

  • IBA Group
  • Lantheus Medical Imaging
  • Triad Isotopes
  • Siemens Healthcare (PETNET Solutions)
  • NTP Radioisotopes
目次
Product Code: 47434

Nuclear medicine therapeutics using radioactive sources includes treatment of the thyroid, pain palliation of bone metastasis and certain other cancers. Research is underway to develop new radiopharmaceuticals to treat different tumors. Recently, due to increasing cancer and cardiac ailments, the burden from these diseases have increased globally. This has helped in the awareness regarding nuclear medicine therapeutics among the population. Hence all these factors have helped in the growth of the market.

However, radioisotopes have short half-life, which results in faster decay. Moreover, the cost of equipment and radioisotopes themselves is high. As a result, many health providers do not invest in these therapies. These have, hence, been restraining the market growth.

Key Market Trends

Application in Oncology is Expected to Dominate the Market

According to World Health Organization (WHO) 2018 data on cancer, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. Moreover, Cancer Research UK suggests that the population suffering from cancer is expected to increase in the future. As per the report, if recent trends in incidence of major cancers and population growth are consistent, it is predicted there will be 27.5 million new cancer cases worldwide each year by 2040. This is an increase of 61.7% from 2018 (17 million as per Cancer Research UK).

Nuclear medicine offers therapeutic procedures, such as radioactive iodine (I-131) therapy that use small amounts of radioactive material to treat the cancer. Non-Hodgkin's lymphoma patients who do not respond to chemotherapy may undergo radioimmunotherapy (RIT), which is a personalized cancer treatment that combines radiation therapy with the targeting ability of immunotherapy, a treatment that mimics cellular activity in the body's immune system. Hence as the incidence of cancer increases, the demand for nuclear medicine therapeutics is also expected to icnrease.

North America is Expected to Show High Growth Over the Forecasted Period

The prevalence of cancer is one of the highest in North American countries of the United States (US) and Canada. Cardiac disorders are also prevalent in the US and Mexico. However, the United States (US) and Canada have a developed and well-structured health care system, and Mexico is also coping up with these counties. These systems thus encourages research and development. These policies encourage global players to enter the US and Canada.

Hence as a result, these countries enjoy the presence of many global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

Majority of the nuclear medicine therapeutics products are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Cancer and Cardiac Ailments
    • 4.2.2 Growing Awareness Regarding the Nuclear Medicine
  • 4.3 Market Restraints
    • 4.3.1 Short Half-Life of Radiopharmaceuticals
    • 4.3.2 High capital investment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Alpha Emitters
      • 5.1.1.1 Radium-223 (RA-223) & Alpharadin
      • 5.1.1.2 Actinium-225 (AC-225)
      • 5.1.1.3 Lead-212 (PB-212)/Bismuth-212 (BI-212)
      • 5.1.1.4 Others
    • 5.1.2 Beta Emitters
      • 5.1.2.1 Iodine-131 (I-131)
      • 5.1.2.2 Yttrium-90 (Y-90)
      • 5.1.2.3 Others
    • 5.1.3 Brachytherapy
      • 5.1.3.1 Cesium-131
      • 5.1.3.2 Iodine-125
      • 5.1.3.3 Others
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology
    • 5.2.3 Thyroid
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia- Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle- East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Actinium Pharmaceutical Inc.
    • 6.1.2 Alpha Tau Medical Ltd
    • 6.1.3 Bayer AG
    • 6.1.4 Fusion Pharmaceuticals
    • 6.1.5 IBA Radiopharma Solutions
    • 6.1.6 RadioMedix Inc.
    • 6.1.7 Telix Pharmaceuticals Ltd
    • 6.1.8 NTP Radioisotopes
    • 6.1.9 Triad Isotopes (Jubilant Life Sciences)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top